Alzheimer's disease (AD) is a neurodegenerative disorder that is characterized by a progressive cognitive decline along with various neuropsychiatric symptoms, including depression and anxiety. Increasing evidence has been proposed the activation of the tryptophan-degrading indoleamine-2,3-dyoxigenase (IDO), the rate-limiting enzyme of kynurerine pathway (KP), as a pathogenic factor of amyloid-beta (Ab)-related inflammation in AD. In the current study, the effects of an intracerebroventricular (i.c.v.) injection of Ab 1-42 peptide (400 pmol/mice; 3 ll/site) on the regulation of KP biomarkers (IDO activity, tryptophan and kynurerine levels) and the impact of Ab 1-42 on neurotrophic factors levels were investigated as potential mechanisms linking neuroinflammation to cognitive/emotional disturbances in mice. Our results demonstrated that Ab 1-42 induced memory impairment in the object recognition test. Ab 1-42 also induced emotional alterations, such as depressive and anxiety-like behaviors, as evaluated in the tail suspension and elevated-plus maze tests, respectively. We observed an increase in levels of proinflammatory cytokines in the Ab 1-42 -treated mice, which led to an increase in IDO activity in the prefrontal cortex (PFC) and the hippocampus (HC). The IDO activation subsequently increased kynurerine production and the kynurenine/tryptophan ratio and decreased the levels of neurotrophic factors in the PFC and HC, which contributed to Ab-associated behavioral disturbances. The inhibition of IDO activation by IDO inhibitor 1-methyltryptophan (1-MT), prevented the development of behavioral and neurochemical alterations. These data demonstrate that brain IDO activation plays a key role in mediating the memory and emotional disturbances in an experimental model based on Ab-induced neuroinflammation.
Introduction
Alzheimer's disease (AD) is a devastating neurodegenerative disorder that is characterized by a progressive loss of memory and mental function, leading to an inability to care for oneself (Bateman et al., 2012) . In addition to cognitive deficits, AD patients frequently exhibit a number of non-cognitive symptoms, namely ''neuropsychiatric symptoms of dementia" (NPSD), such as depression and anxiety (Cerejeira et al., 2012; Rosenberg et al., 2015) . NPSD comprise the major component of the disease burden for patient and caregivers and are associated with a more rapid disease progression to severe dementia and death (Peters et al., 2015) . The amyloid-beta (Ab) cascade hypothesis of AD pathogenesis postulates that the Ab accumulation in the brain triggers a cascade of pathological processes that causes a progressive synaptic dysfunction and neuronal loss; ultimately leading to cognitive decline (Ballard et al., 2011) .
Emerging evidence suggests that neuroinflammation plays a causal role in AD pathogenesis (Heneka et al., 2015; Heppner et al., 2015) . It has been widely recognized that chronic neuroinflammation induced by a number of proinflammatory cytokines, such as interleukin-1beta (IL-1b), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-a) released from activated microglia and astrocytes, is an early and continuous feature of the AD brain (Heppner et al., 2015; Wang et al., 2015) . This inflammatory response may be responsible for the development of behavioral disturbances in AD, such as cognitive impairment (Souza et al., 2013) http://dx.doi.org/10.1016/j.bbi.2016.03.002 0889-1591/Ó 2016 Elsevier Inc. All rights reserved. and neuropsychiatric symptoms (dos Santos et al., 2013; Holmgren et al., 2014; Takeda et al., 2014) .
While the mechanism underlying neuroinflammation-induced AD pathology remains not fully elucidated, increasing evidence suggests that the kynurenine pathway (KP) may play an important role (Bonda et al., 2010; Maddison and Giorgini, 2015; Tan et al., 2012; Wu et al., 2013) . The KP is the major metabolic route for tryptophan catabolism in the mammalian tissues, which leads to the production of kynurenine and downstream metabolites that have been closely related to the pathogenesis of AD (Gulaj et al., 2010; Kincses et al., 2010) . It has been shown that the induction of the first and rate-limiting enzyme of KP, indoleamine-2,3-dyoxigenase (IDO), which is primarily generated by glial cells in the brain, is driven by proinflammatory cytokines (Maes et al., 2011; Stone and Darlington, 2002) . Importantly, IDO was found to be highly expressed in the hippocampus of AD mice and of AD patients, specifically co-localized with pathological hallmarks of AD, such as senile plaques and neurofibrillary tangles (Wu et al., 2013) . Accordingly, it has been proposed that the stimulation of the KP by proinflammatory cytokines could be involved with the neurodegenerative pathways in AD (Kincses et al., 2010; Tan et al., 2012) .
A recent study shows that in a mouse model of inflammationassociated depression, the induction of IDO is related to the down-regulation of brain-derived neurotrophic factor (BNDF) in the prefrontal cortex and hippocampus of mice (Gibney et al., 2013) , two brain regions that are critical components of the cortical-hippocampal circuitry for declarative memory (Eichenbaum, 2000) . In fact, the expression of many neurotrophic factors were markedly reduced in the brain of AD patients (Allen et al., 2011; Holsinger et al., 2000) and AD mouse models (Fukomoto et al., 2014; Shin et al., 2014) . Neurotrophic factors are important for driving neurogenesis, synaptic plasticity and neuronal survival (Park and Poo, 2013) , which are all processes affected by the pathogenesis of AD (Sopova et al., 2014) . Therefore, a neurotrophic deficiency could be an additional mechanism implicated with IDO activation by pro-inflammatory cytokines in AD brain. Several previous studies have described that a single intracerebroventricular (i.c.v.) injection of synthetic Ab peptides Ab 1-40 and Ab , is a useful rodent model for the characterization of Abinduced inflammatory and neurotoxic responses, because it mimics the early behavioral alterations observed in AD (Chambon et al., 2011; Chen et al., 2015; Fukumoto et al., 2014; Piermartiri et al., 2010; Rammes et al., 2015; Szczepanik and Ringheim, 2003; Souza et al., 2013) . Although the model is unable to induce all of the pathological AD hallmarks, such as amyloid plaque and phospho-tau positive cells, the central injection of Ab peptides is a paradigm that supports the hypothesis of a key pathogenic role of oligomeric Ab (Chambon et al., 2011) and enables preclinical evaluation of drugs targeting Ab (Van Dam and De Deyn, 2011) . Despite extensive studies demonstrating cognitive deficits related to this paradigm, the mechanisms of Ab-induced neurotoxicity and its effects on non-cognitive disturbances remains not completely understood. In particular, the connections between Abmediated inflammation and activation of IDO in the brain, and how this contributes to behavioral alterations are unknown.
Thus, the objective of this study was to characterize the mechanisms by which the i.c.v. injection of Ab 1-42 peptide induces cognitive impairment and emotional alterations, such as depressive and anxiety-like behaviors in mice, secondary to its neuroinflammatory actions. Moreover, neurochemical parameters related to inflammatory status, neurotrophic factors and KP activation were evaluated in the prefrontal cortex and hippocampus in an attempt to elucidate the potential mechanisms that link neuroinflammation to behavioral disturbances. A competitive inhibitor of IDO, 1-methyl-tryptophan (1-MT), was used to investigate the involvement of IDO in the mechanisms of Ab toxicity.
Methods

Animals
Experiments were performed using male Swiss Albino mice (30-40 g, 90 days old). Animals were maintained at 22-25°C with free access to water and food, under a 12:12 h light/dark cycle, with lights on at 7:00 a.m. All manipulations were carried out during light phase on the day. All efforts were made to minimize animal suffering and to reduce the number of animals used. The procedures of this study were conducted according to the guidelines of the Committee on Care and Use of Experimental Animals Resources and with the approval of Ethical Committee for Animal Use (CEUA protocol # 012/2012) of Federal University of Pampa, Brazil.
Experimental design
Two experiments were conducted. In the first experiment, mice (n = 8 animals per group) received an i.c.v. injection of Ab 1-42 to investigate the behavioral disturbances and neurochemical parameters in a time-course curve (times: 6 h, 1, 3 and 7 days) (Fig. 1) .
In the second experiment, mice were divided into four groups (n = 8 animals per group): vehicle + PBS (sham-operated); 1-MT + PBS; Ab + vehicle; and Ab + 1MT. Seven days after the i.c.v. injection of Ab 1-42 (peak effect), mice were subjected to behavioral tests. Afterwards, they were euthanized and the prefrontal cortex and hippocampus were removed for neurochemical assays (Fig. 1 ).
Drug treatment protocol
Ab 1-42 (Sigma-Aldrich) was prepared as stock solution at a concentration of 1 mg/ml in sterile 0.1 M phosphate-buffered saline (PBS) (pH 7.4), and aliquots were stored at À20°C. Ab 1-42 was aggregated by incubation at 37°C for 4 days before use, as described previously (Souza et al., 2013) . The aggregated form of Ab 1-42 (400 pmol/mouse) was administered by i.c.v. injection, using a microsyringe with a 28-gauge stainless-steel needle 3.0 mm long (Hamilton), as described previously (Cioanca et al., 2015; Piermatini et al., 2010; Yan et al. 2001) . Briefly, mice were anesthetized with intraperitoneal (i.p.) injection of sodium pentobarbital (0.067 mg/g) and placed in a stereotaxic apparatus (Insight, Brazil). Under light anesthesia (i.e. just that necessary for loss of the postural reflex), the needle was inserted unilaterally 1 mm to the right of the midline equidistant from each eye and 1 mm posterior to a line drawn through the anterior base of the eyes (used as external reference). Ab 1-42 was administered rightunilaterally into the lateral ventricle. The injection volume of 3 ll of Ab 1-42 or PBS was delivered gradually (1 ll/min) using the following coordinates from bregma: anteroposterior (AP) = À0.1 mm, mediolateral (ML) = 1 mm, and dorsoventral (DV) = À3 mm. The sham-operated mice were injected with PBS (3 ll/site; i.c.v.). The advantage of this i.c.v. route of administration is the rapid distribution of the peptide throughout the brain (Chambon et al., 2011) . In order to confirm the accurate placement of the injection site (needle track) at the time of brain dissection, two mice in each group were submitted to dye injection (Evans blue dye, 0.5 ll) into the ventricles (Davisson et al., 1998) .
A non-selective racemic mixture of 1-MT (1-Methyl-D,Ltryptophan; Sigma-Aldrich) was administered through subcutaneous (s.c.) injection at a dose of 50 mg/kg in a volume of 5 ml/ kg, as described earlier (Xie et al., 2014) . The injections were administered twice daily at 12-h intervals for 7 days before Ab injection. According to Xie et al. (2014) , this drug schedule was in accordance with the methods of Professor Keith W. Kelley, who administered 50 mg/kg of 1-MT to mice twice a day with an equal effect to that observed in studies using 5 mg/day pellets (e.g., the study of O'Connor et al., 2009 ). We prepared 1-MT using 0.1 M NaOH and adjusted the pH to 9.0 using 1 M HCl. The sham-operated and Ab + vehicle groups were injected with vehicle (normal saline solution) at a volume of 5 ml/kg (s.c.).
Behavioral assessment
During a period of 2 days after i.c.v. injection of Ab 1-42 (starting 1, 3 and 7 days after Ab 1-42 injection in experiment 1, and starting 7 days after Ab 1-42 injection in experiment 2), the animals were subjected to a battery of behavioral paradigms that included the open-field test and the object recognition test (day 1), and the tail suspension test and the elevated plus-maze task (day 2). In order to minimize the potentially negative effects of stress on cognitive performance of the animals, we separated the emotional tests from the object recognition test. Moreover, it is noteworthy that on day 1, the open-field test was also used as the habituation phase for object recognition test. All tests were carried out between 9:00 and 16:00 h and they were scored by the same trained raters (who were blind to the experimental treatments) in an observation room where the mice had been habituated for at least 1 h before the beginning of the tests.
Open-field test (OFT)
The OFT was carried out to evaluate whether the drugs affected locomotor activity. The animals were subjected to an OFT apparatus (Insight Ltd., Ribeirao Preto, SP, Brazil) individually for a period of 5 min. The total distance (unit: mm) was computed and used for analysis (Goes et al., 2014; Prut and Belzung, 2003) .
Object recognition test (ORT)
After the OFT, the memory function of mice was assessed with the ORT. The task is based on the spontaneous tendency of rodents towards novelty. Specifically, when they are first exposed to two identical objects, rodents will then explore one of the objects (preference of a novel object) for a longer time than they explore the familiar object. This test requires no external motivation, reward, or punishment and very little training or habituation is required (Winters et al., 2008) . The ORT was performed as described by Ennaceur and Delacour (1988) with some modifications. Mice were placed in an open box (similar to OFT), were allowed to explore two identical objects (sample phase) for 5 min, and were subsequently returned to their home cage. To evaluate short-term memory, mice were returned to the open box, after a delay of 90 min (intertrial interval), where they were exposed to two different objects (test phase), one was identical to the one previously encountered in the sample phase, therefore now familiar, and the other was novel. The animals were allowed to explore both objects for more 5 min. After each trial, the box and objects were cleaned with 70% ethanol. The positions of the objects in the test and the objects used as novel or familiar were counterbalanced between the animals. Exploratory behavior was defined as sniffing or touching the object with the nose and/or forepaws. Any other behavior, such as sitting on or turning around the object was not considered as exploration. The amount of time each animal spent actively investigating the objects was manually scored and the recognition index was calculated as the time exploring novel or familiar object divided by the total time spent exploring both objects.
Tail suspension test (TST)
The second day of behavioral assessments started with the TST. Mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. The immobility time was recorded for 6 min. The immobility behavior was defined according to the method described by Steru et al. (1985) .
Elevated plus-maze test (EPMT)
Three hours after the TST, the EPMT was used to evaluate anxiety-like behavior in the mice, in accordance with the method of Pellow et al. (1985) . The experimental apparatus (Insight Ltd., Ribeirao Preto, SP, Brazil) was shaped as a plus sign and consisted of two open arms (30 Â 5 cm) and two equal-sized closed arms (30 Â 5 Â 15 cm) extending from a common central platform (5 Â 5 cm). The maze was made of opaque grey PVC and was kept elevated at a height of 50 cm above the floor. The experiments were conducted in a sound-attenuated room under low intensity light (12 lx). The animals were individually placed in the central area of the maze facing an enclosed arm and were observed for 5 min. The apparatus was cleaned with an ethanol solution (10% v/v) and dried with paper towels after each trial in order to prevent odors from carrying-over between trials. During a 5 min test period, the number of entries either the open or enclosed arms, plus the time spent in the open arms we recorded. An entry was defined as placing all four paws within the boundaries of the arm. The following measures were obtained from the test: (a) the time spent in the open arms compared to the total time spent in the plus-maze (300 s); (b) the number of entries into the open arms; (c) the number of entries into the closed arms. In this test, the anxiolytic effect of a drug is defined by a significant increase in the entries/or time spent in the open arms (Clénet et al., 2006) .
Tissue preparation for neurochemical determinations
After behavioral tests, mice were euthanized with barbiturate overdose (pentobarbital sodium 150 mg/kg; i.p. route) and transcardially perfused with 10 ml ice-cold saline via the aorta. The brain dissection was performed according to the method of Spijker (2011) , a method to dissect multiple brain regions from a single brain based on existing atlases (Williams, 1999) . Prefrontal cortex and hippocampus were bilaterally removed and rapidly homogenized in 50 mM Tris-Cl, pH 7.4. The homogenate was centrifuged at 2400Âg for 15 min at 4°C and a low-speed supernatant fraction (S1) was used for assays.
2.6. Neurochemical assays 2.6.1. Cytokine levels Levels of interferon-gamma (IFN-c), tumour necrosis factoralpha (TNF-a), interleukin 1-beta (IL-1b) and interleukin-10 (IL-10) in the prefrontal cortex and hippocampus were measured using sample aliquots of 100 ll and mouse cytokine ELISA DuoSet Kits from R&D Systems (Minneapolis, MN, USA), according to the manufacturer's instructions (protein range of 31.25-2000 pg). The level of cytokine was estimated by interpolation from a standard curve by colorimetric measurements at 450 nm (correction wavelength 540 nm) on an ELISA plate reader (Berthold Technologies-Apollo 8-LB 912, KG, Germany). Results are shown as pg/mg of tissue.
Neurotrophic factors levels
Protein levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF) were measured using a commercially available sandwich enzyme-linked immune sorbent assay (ELISA) kit (Chemicon International, Temecula, CA, USA) according to the manufacturer's instructions. BDNF and NGF levels were evaluated in S1 of prefrontal cortex and hippocampus. The BDNF, NGF and GDNF levels were expressed as pg/mg wet weight of tissue.
Tryptophan (TRP) and kynurenine (KYN) levels
The levels of TRP and its metabolite KYN in the prefrontal cortex and hippocampus were performed in a Shimadzu LC-10A liquid chromatograph, according to Silva et al. (2002) . The chromatographic separation was achieved using a 250-by 4.6-mm (inner diameter) C 18 reverse-phase column (particle size, 4 lm; Aquapore RP-300 C-18). For Trp measurement, the column was eluted isocratically at flow rate of 1.0 ml/min with 0.015 M sodium acetate (pH 4.5) containing 15% methanol. For KYN determination, the column was eluted with acetonitrile at a 1:47 dilution in 0.1 M acetic acid-0.1 M ammonium acetate (pH 4.65). The absorbance of the column effluent was monitored at 280 and 365 nm for TRP and KYN respectively. The peaks of TRP or KYN were identified by comparison with the retention times of standard compounds (Sigma), and quantification was based on the ratios of the peak areas of compound to the internal standard. The tissue levels were expressed in pg/mg tissue.
2.6.4. Indoleamine-2,3-dyoxigenase (IDO) activity IDO activity in the prefrontal cortex and hippocampus was determined as previously described (Lestage et al., 2002) . The supernatants (0.2 ml) were added to 0.8 ml of the reaction mixture containing 400 lM L-tryptophan, 20 mM ascorbate, 10 lM methylene blue, and 100 lg catalase in 50 mM potassium phosphate buffer pH 6.5. The reaction was carried out at 37°C under agitation for 60 min. Then, it was blocked by adding 0.2 ml of 30% trichloroacetic acid and further incubated at 50°C for 30 min to convert the N-formylkynurenine to L-kynurenine. Samples were centrifuged at 13,000Âg for 10 min at 4°C. The supernatants were filtered through microspin ultrafiltrates with a cut-off of 10,000 M r before being taken for measurement of IDO.
The amount of L-kynurenine formed from TRP was determined by reversed phase high pressure liquid chromatography (HPLC).
One hundred ll of the reaction product was injected onto a Merck LiChrospher column (150 mm long, 4.6 mm diameter, packed with 5 lm silica beads holding 18C long carbon chains). A cartridge guard column containing the same material as the analytical column was used. The mobile phase consisted of 0.1 M ammonium acetate buffer (pH 4.65) with 5% acetonitrile. Flow rate was 1 ml/min. KYN was detected using a spectrometer measuring absorbency at a wavelength of 365 nm and was quantified using known amounts of L-kynurenine. The retention time of KYN was around 5.35 min. All determinations were performed in duplicate. One unit of the activity was defined as 1 nmol KYN/h/mg protein at 37°C.
Protein determination
Protein concentration was measured by the method of Bradford (1976) , using bovine serum albumin as the standard.
Statistical analysis
The data distribution was verified by applying the KolmogorovSmirnov test. The results are presented as means ± standard error medium (SEM). Comparisons between the experimental and the control groups were performed by one-way analysis of variance (ANOVA), followed by Tukey post hoc test or two-way ANOVA, followed by Bonferroni post hoc test, when appropriate. A value of P < 0.05 was considered to be statistically significant. All tests were carried out using the GraphPad software 5.0 (San Diego, California, USA).
Results
The i.c.v. injection of Ab 1-42 affected cognitive and emotional behaviors
The injection of Ab 1-42 , at 3 and 7 days before the ORT, decreased the recognition index compared to the PBS treated control (sham-operated) group, thereby inducing a memory impairment (Ab 1-42 Â time interaction, F 1,24 = 6.23, p < 0.01; Ab 1-42 , F 1,24 = 56.04, p < 0.001). Post hoc comparisons demonstrated that the peak effect occurred at 7 days after Ab injection (p < 0.001; Fig. 2A ). Moreover, it is important to emphasize that the deficit in the ORT observed in Ab-treated mice cannot be explained by a general reduced interest for novelty, as there were no differences observed among animal groups in the total investigation time (i.e., the sum of the time that animals spent investigating the two objects) during both the training and the test phases (data not shown).
Injection of Ab 1-42 before TST significantly increased the immobility time when compared to PBS treated controls, which is interpreted as a depressive-like effect (Ab 1-42 Â time interaction, F 1,24 = 9.33, p < 0.01; Ab 1-42 , F 1,24 = 26.90, p < 0.001; time, F 1,24 = 5.95, p < 0.01). Post hoc comparisons demonstrated that injection of Ab 1-42 produced a depressive-like effect at 7 days (p < 0.001; Fig. 2B ).
When exposed to the EPMT, Ab-treated mice showed a significant reduction in the time spent on open arms, indicating anxiety-like behavior (Ab 1-42 Â time interaction, F 1,24 = 5.55, p < 0.01). Post hoc comparisons demonstrated that anxiety-like behavior was more evident 7 days after Ab 1-42 injection (p < 0.001; Fig. 2C ). No significant differences among groups were observed in the number of open-arms and enclosed-arm entries (data not shown). Moreover, the Ab 1-42 injection did not cause significant alterations in the distance traveled in the OFT (Ab 1-42 Â time interaction, F 1,24 = 0.04, p = 0.96; Ab 1-42 , F 1,24 = 0.02, p = 0.88; time, F 1,24 = 0.29, p = 0.75).
The i.c.v. injection of Ab 1-42 induced neuroinflammation in the prefrontal cortex and hippocampus
The neuroinflammation induced by Ab 1-42 was characterized by increased levels of the pro-inflammatory cytokines IFN-c, TNF-a, IL-1b and decreased levels of the anti-inflammatory cytokine IL-10.
In response to Ab 1-42 injection, a significant increase in IFN-c levels was found in the prefrontal cortex compared to PBS treated controls (F 4,35 = 97.02, p < 0.001). Post hoc comparisons showed that the injection of Ab 1-42 increased IFN-c levels at 1, 3 and 7 days. The peak effect occurred at the 1 day time point (p < 0.001; Fig. 3A) . IFN-c levels also increased in the hippocampus compared to PBS treated controls (F 4,35 = 29.51, p < 0.001). Post hoc comparisons revealed that the maximal effect occurred 7 days after Ab 1-42 injection (p < 0.001; Fig. 3B ).
Ab-treated mice showed a significant increase in TNF-a levels in the prefrontal cortex (F 4,35 = 49.24, p < 0.001) compared to PBS treated controls. Post hoc comparisons showed that the injection of Ab 1-42 increased TNF-a levels at 1, 3 and 7 days. The peak effect occurred at 7 days (p < 0.05; Fig. 3C ). A similar pattern of TNF-a levels was found in the hippocampus with the most significant increase occurring at 7 days post administration (p < 0.001) (F 4,35 = 15.87, p < 0.001; Fig. 3D) .
A significant increase in IL-1b levels was also observed in the prefrontal cortex (F 4,35 = 26.81, p < 0.001) and hippocampus (F 4,35 = 40.73, p < 0.001) in Ab-treated mice compared to PBS treated controls. Post hoc comparisons showed that the levels of IL-1b increased significantly 1, 3 and 7 days after Ab 1-42 injection in both brain regions, with a peak effect at 7 days (p < 0.001; Fig. 3E and F, respectively).
Ab 1-42 injections caused a significant decrease in IL-10 levels in the prefrontal cortex compared to PBS treated controls (F 4,35 = 24,61, p < 0.001). Post hoc comparisons showed that the injection of Ab 1-42 decreased IL-10 levels at 1, 3 and 7 days. The peak effect occurred at 7 day time point (p < 0.001; Fig. 3G ). A significant decrease in IL-10 levels was observed in the hippocampus of Ab-treated mice compared to PBS treated controls at 1 day, 3 days and 7 day, again with maximal effect at 7 days post Ab 1-42 injection (p < 0.01) (F 4,35 = 8.393, p < 0.001; Fig. 3H ). Ab-treated mice showed a significant decrease in BDNF levels in the prefrontal cortex compared to PBS treated controls (F 4,35 = 13.47, p < 0.001). Post hoc comparisons showed that the injection of Ab 1-42 decreased BDNF levels at 1, 3 and 7 days of the time points. The peak effect occurred at 7 days (p < 0.001; Fig. 4A) . A similar pattern of BDNF levels was found in the hippocampus with the most significant increase occurring at 7 days post-injection (p < 0.001) (F 4,35 = 18.00, p < 0.001; Fig. 4B ).
In response to Ab 1-42 injection, NGF levels were significantly reduced in the prefrontal cortex at 1, 3 and 7 days (p < 0.05, p < 0.05 and p < 0.001, respectively) (F 4,35 = 10.51; p < 0.001; Fig. 4C ). In the hippocampus, reduced NGF levels were found at 7 days post administration (p < 0.01) (F 4,35 = 10.69, p < 0.001; Fig. 4D ).
Decreased levels of GDNF were observed in prefrontal cortex at 7 days post Ab 1-42 administration (p < 0.05) (F 4,35 = 5.339, p < 0.01; Fig. 4E ). A decrease in GDNF levels was also detected in the hippocampus in response to Ab 1-42 7 days post injection (p < 0.05) (F 4,35 = 4.713, p < 0.01; Fig. 4F ). 3.4. The i.c.v. injection of Ab 1-42 caused IDO activation coupled with an increase of TRP levels and KYN production in the prefrontal cortex and hippocampus A significant increase in IDO activity was found in the prefrontal cortex of Ab-treated mice when compared to control animals (F 4,35 = 48.83, p < 0.001). Post hoc comparisons showed that the injection of Ab 1-42 increased IDO activity in a time-dependent manner. The peak effect occurred at 7 days (p < 0.001; Fig. 5A ). In a similar fashion, an increase in IDO activity was found in hippocampus when compared to PBS treated controls (F 4,35 = 32.24, p < 0.001). Post hoc comparisons revealed that the maximal effect occurred 7 days after Ab 1-42 injection (p < 0.001; Fig. 5B ).
Increased levels of TRP were observed in prefrontal cortex at 7 days post Ab 1-42 administration (p < 0.05) (F 4,35 = 5.108, p < 0.01; Fig. 5C ). In the hippocampus, increased TRP levels was found at 3 and 7 days post administration, again with peak effect at 7 days (p < 0.001) (F 4,35 = 12.78, p < 0.001; Fig. 5D ).
When compared to PBS treated controls, mice exposed to Ab 1-42 showed a significant increase in the levels of KYN in the prefrontal cortex at 1, 3 and 7 days post administration (p < 0.001) (F 4,35 = 47.21, p < 0.001; Fig. 5E ). This translated to an increased KYN/TRP ratio at 1, 3 and 7 days post-Ab administration (p < 0.001) (F 4,35 = 16.67, p < 0.001; Fig. 5F ). Similarly, the levels of KYN produced in the hippocampus was significantly higher at 1, 3 and 7 days post Ab 1-42 injection (p < 0.01, p < 0.001, p < 0.001, respectively) (F 4,35 = 41.76, p < 0.001; Fig. 5G ). Once again this increase in KYN translated to an increase in the KYN/TRP ratio at 1, 3 and 7 days (p < 0.001) (F 4,35 = 26.34, p < 0.001; Fig. 5H ).
Ab 1-42 -induced behavioral disturbances is blocked by 1-MT pretreatment
In experiment 2, mice were pretreated with 1-MT during 7 days before i.c.v. injection of Ab 1-42 . Memory function, non-cognitive behaviors and locomotor activity were assessed starting at 7 days (peak effect) post-Ab injection.
Two-way ANOVA of recognition index in ORT demonstrated a significant effect of (Table 1) . 
Ab 1-42 -induced neuroinflammation is attenuated by 1-MT
Two-way ANOVA of IFN-c levels in the prefrontal cortex demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 69.02, p < 0.001). Post hoc comparisons revealed that 1-MT pretreatment attenuated the increase of IFN-c levels caused by Ab 1-42 (p < 0.001; Fig. 7A ). Similarly, two-way ANOVA of IFN-c levels in the hippocampus yielded a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 56.30, p < 0.001). Post hoc comparisons showed that the increased IFN-c levels observed in the hippocampus of Ab-treated mice was mitigated by 1-MT pretreatment (p < 0.001; Fig. 7B ).
Statistical analysis of TNF-a in the prefrontal cortex demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 57.56, p < 0.001). Post hoc comparisons revealed that the increase of TNF-a induced by Ab 1-42 was significantly attenuated by 1-MT pretreatment (p < 0.001; Fig. 7C ). As with the prefrontal cortex, statistical analysis of TNF-a in the hippocampus yielded a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 83.26, p < 0.001). Post hoc comparisons showed that the increased TNF-a levels observed in the hippocampus of Ab-treated mice was mitigated by 1-MT pretreatment (p < 0.001; Fig. 7D ).
Two-way ANOVA of IL-1b levels in the prefrontal cortex demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 41.51, p < 0.001). Post hoc comparisons revealed that 1-MT pretreatment attenuated the increase of IL-1b levels caused by Ab 1-42 (Fig. 7E) . Similarly, two-way ANOVA of IL-1b levels in the hippocampus yielded a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 45.58, p < 0.001). Post hoc comparisons showed that the increased IL-1b levels observed in the hippocampus of Ab-treated mice was mitigated by 1-MT pretreatment (p < 0.001; Fig. 7F ).
Statistical analysis of IL-10 in the prefrontal cortex demonstrated a significant main effect of Ab 1-42 (F 1,24 = 46.97, p < 0.001) and 1-MT pretreatment (F 1,24 = 7.47, p < 0.05). Post hoc comparisons revealed that Ab 1-42 significantly reduced IL-10 levels in the prefrontal cortex of mice compared to sham group (p < 0.001). 1-MT pretreatment partially protected against the decrease of IL-10 induced by Ab 1-42 (p < 0.05; Fig. 7G ). In the hippocampus, statistical analysis of IL-10 yielded a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 9.00, p < 0.05). Post hoc comparisons showed that the decrease in IL-10 levels of Ab-treated mice was mitigated by 1-MT pretreatment (p < 0.05; Fig. 7H ). Data are expressed as the mean ± S.E.M. (n = 8). Two-way ANOVA revealed no significant differences among experimental groups in any of the parameters evaluated.
decrease of BDNF levels is normalized by 1-MT pretreatment (p < 0.001; Table 2 ). In the hippocampus, two-way ANOVA of BDNF levels yielded a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 21.42, p < 0.001). Post hoc comparisons showed that 1-MT pretreatment significantly protected against Ab-induced BDNF deficit (p < 0.001; Table 2 ). Statistical analysis of NGF levels in prefrontal cortex demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 6.43, p < 0.05). Post hoc comparisons revealed that the decrease of NGF levels induced by Ab 1-42 was significantly prevented by 1-MT pretreatment (p < 0.01; Table 2 ). As with the prefrontal cortex, statistical analysis of NGF in the hippocampus yielded a significant Ab 1-42 Â 1-MT interaction F 1,24 = 7.36, p < 0.05. Post hoc comparisons showed that the decreased NGF levels observed in the hippocampus of Ab-treated mice was also prevented by 1-MT pretreatment (p < 0.01; Table 2 ). Two-way ANOVA of GDNF levels in the prefrontal cortex demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 8.03, p < 0.05). Post hoc comparisons revealed that 1-MT pretreatment attenuated the decrease of GDNF levels caused by Ab 1-42 (p < 0.01; Table 2 ). In the hippocampus, two-way ANOVA of GDNF levels showed a significant main effect of Ab 1-42 (F 1,24 = 17.69, p < 0.01) and a main effect of 1-MT (F 1,24 = 88.62, p < 0.001). Post hoc comparisons revealed that the injection of Ab 1-42 significantly reduced the GDNF levels (p < 0.05). 1-MT pretreatment markedly abrogated the GDNF deficit induced by Ab 1-42 (p < 0.05; Table 2 ).
3.7.1. 1-MT blocks Ab 1-42 -induced brain IDO activation Two-way ANOVA of IDO activity in the prefrontal cortex demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 42.55, p < 0.001). Post hoc comparisons revealed that Ab 1-42 injection significantly increased IDO activity when compared to sham group (p < 0.001). 1-MT pretreatment notably blocked the induction of IDO induced by Ab 1-42 (p < 0.001; Fig. 8A ). In a similar manner, two-way ANOVA of IDO activity in the hippocampus demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 20.03, p < 0.001). Post hoc comparisons showed that the injection of Ab 1-42 significantly increased IDO activity in the hippocampus (p < 0.001). Once again 1-MT significantly blocked the induction of IDO induced by Ab 1-42 (p < 0.001; Fig. 8B ).
3.8. The increase of TRP levels and KYN production elicited by Ab 1-42 is abrogated by 1-MT pretreatment Two-way ANOVA of TRP levels in the prefrontal cortex demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 14.99, p < 0.01). Post hoc comparisons revealed that the Ab-induced increase of TRP levels is normalized by 1-MT pretreatment (p < 0.001; Fig. 9A ). Similarly, two-way ANOVA of TRP levels in the hippocampus revealed a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 22.06, p < 0.001). Post hoc comparisons demonstrated that 1-MT pretreatment significantly abrogated the increase of TRP levels in the hippocampus induced by Ab 1-42 (p < 0.001; Fig. 9B ).
Statistical analysis of KYN levels in prefrontal cortex yielded a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 106.00, p < 0.001). Post hoc comparisons revealed that the increase of KYN levels induced by Ab 1-42 was significantly mitigated by 1-MT pretreatment (p < 0.001; Fig. 9C ). As with the prefrontal cortex, statistical analysis of KYN levels in the hippocampus demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 43.44, p < 0.001). Post hoc comparisons showed that the increased KYN levels observed in the hippocampus of Ab-treated mice was also prevented by 1-MT pretreatment (p < 0.001; Fig. 9D ).
Two-way ANOVA of KYN/TRP ratio in the prefrontal cortex demonstrated a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 118.10, p < 0.001). Post hoc comparisons revealed that the Ab-induced increase of KYN/TRP ratio is attenuated by 1-MT pretreatment (p < 0.01; Fig. 9E ). In similar manner, two-way ANOVA of KYN/TRP ratio in the hippocampus yielded a significant Ab 1-42 Â 1-MT interaction (F 1,24 = 36.06, p < 0.001). Post hoc comparisons showed that 1-MT pretreatment significantly abrogated the increase of TRP levels in the hippocampus induced by Ab 1-42 (p < 0.01; Fig. 9F ).
Discussion
In the present study we sought to investigate the potential mechanisms that link neuroinflammation and cognitive/emotional alterations induced by an i.c.v. injection of Ab 1-42 in mice. The Ab 1-42 peptide was chosen due to its increased level of neurotoxicity (Chambon et al., 2011) and to its ability to induce IDO activation in contrast to Ab 1-40 (Guillemin et al., 2003) . Although more studies are needed to confirm this, a reasonable explanation for the activation of IDO by Ab 1-42 and not by Ab 1-40 , is due to its strong stimulation of IFN-c, a potent cytokine inducer of IDO (Yamada et al., 2009 ).
The i.c.v. injection of Ab 1-42 induced cognitive and emotional disturbances
The present study demonstrates that Ab 1-42 -treated mice, as expected, displayed a poor performance in the object recognition test (ORT), which is highly dependent upon the function of the hippocampal and prefrontal cortex regions (Warburton and Brown, 2015) . Because the ORT is used to evaluate declarative memory and object recognition has shown to be impaired in patients with AD (Winters et al., 2008) , this test has an important application in the study of AD (Antunes and Biala, 2012 ). The time course shows that the impairment of recognition memory in the ORT occurred at 3 days and 7 days after Ab 1-42 administration, with a maximal effect at 7 days. Due to the short retention time (90 min) used in the present study, we suggest that the Ab 1-42 caused a deterioration in short-term memory, which is a common and early symptom of AD (Antunes and Biala, 2012) . From a mechanistic perspective, the Ab neurotoxicity could have effects on the encoding and consolidation of object characteristics that were reflected by a decreased preference for the novel object during the test phase.
In addition to progressive memory loss, AD patients frequently exhibited NPSD, including depression and anxiety, which are strongly correlated with the degree of functional and cognitive impairment, worsen the disease progress (Cerejeira et al., 2012) . In order to investigate whether such behaviors are affected in Ab 1-42 -treated mice, we resort to the tail suspension test (TST) and elevated plus-maze test (EMPT), two behavioral paradigms widely used for the screening of antidepressants and anxiolytic drugs, respectively (Castagné et al., 2006 ). Our results demonstrate that the cognitive impairments in mice occurred together with emotional responses measured by the TST and EPMT 7 days following Ab 1-42 administration, resembling the emotional disturbances observed in AD patients. Thus, our data corroborate clinical observations and provides additional evidence that the cognitive dysfunction accompanies depression and psychobehaviorals signs and symptoms in early stages of AD (Cerejeira et al., 2012) .
The i.c.v. injection of Ab 1-42 induced a neuroinflammatory response and a neurotrophic deficiency
There is a considerable amount of evidence suggesting that neuroinflammation is involved in the mechanisms of Ab-induced neurotoxicity (Chen et al., 2015; Souza et al., 2013) and AD pathogenesis (Heneka et al., 2015; Heppner et al., 2015; Wang et al., 2015) . In both lipopolysaccharide (LPS)-induced and paraquat models of Parkinson's disease, a strong link has been made between depression-anxiety symptoms and inflammation (Litteljohn et al., 2008) . In the present study, increased levels of IL-1b, TNF-a and IFN-c and decreased levels of IL-10 were detected in the prefrontal cortex and hippocampus of mice 1 day, 3 days and 7 days following Ab 1-42 administration. The maximal levels were found at 7 days, a time at which behavioral disturbances were also most evident. An important finding of our study was the biphasic response of IFN-c in the prefrontal cortex, which was composed of an initial exponential increase 1 day after the Ab 1-42 injection, followed by a decrease at the times 3 and 7 days. In regard to IL-10, it is one of the main anti-inflammatory cytokines that plays an important role in cell survival and neuronal homeostasis, playing a brain-protective effect (Zhang and Jiang, 2015) . Together with the literature, the current study supports and extends the notion that an inflammatory response, reflected by a cytokine dysregulation in brain regions implicated with memory and executive function, can be an important neurobiological mechanism of Abinduced cognitive impairment and emotional alterations in mice. Neurotrophic factors are proteins that play a vital role in regulating all aspects of neural circuit development and function in the mammalian brain, including neuronal survival, synaptic plasticity, neurogenesis, memory consolidation and the pathophysiology of AD (Allen et al., 2011 (Allen et al., , 2013 Budni et al., 2015; Park and Poo, 2013; Sopova et al., 2014) . In this study, the time-course curve shows that the i.c.v. injection of Ab 1-42 induced a neurotrophic deficiency that peaked at the 7 day time point, as measured by the reduction in BDNF, NGF and GDNF levels in the prefrontal cortex and hippocampus of mice. Therefore, we suggest that the neurotrophic deficiency in the prefrontal cortex and hippocampus that occurs in response to Ab 1-42 injection is related to the observed impairments in recognition memory, depressive-like and anxietylike behaviors. 4.3. The i.c.v. injection of Ab 1-42 increased IDO activity and KYN production without depleting TRP levels It has been proposed that IDO plays a pivotal role in the pathogenesis of AD (Bonda et al., 2010; Kincses et al., 2010; Maddison and Giorgini, 2015; Tan et al., 2012) . It is known that the increase in proinflammatory cytokines triggers IDO activation under conditions of brain inflammation (Guillemin and Brew, 2002) . In the present study, we demonstrated that Ab 1-42 induced an increase in IDO activity in the prefrontal cortex and hippocampus of mice 3 days and 7 days post-injection. This activation of IDO coincides temporally with the appearance of the memory impairment and emotional alterations, indicating a key role for this enzyme in early behavioral disturbances of AD. The increase of IDO activity in response to Ab 1-42 occurred 48 h after the increase of proinflammatory cytokines, supporting the notion for a major role of these substances in the induction of IDO. It is worth highlighting that the IFN-c demonstrated to be the main activating factor of IDO, corroborating a previous in vitro study that showed that the priming effect of Ab 1-42 for the IDO induction is mediated by IFNc (Yamada et al., 2009) . In accord with our study, Wu et al. (2013) have reported that higher immunoreactivity of IDO and tryptophan-2,3-dioxigenase (TDO), another initial enzyme of the KP, was observed in the hippocampus of AD patients. Therefore, we demonstrate for the first time that a single i.c.v. injection of Ab 1-42 causes IDO activation in the prefrontal cortex and hippocampus of mice. Further investigation is also necessary to clarify the involvement of TDO in amyloid-related inflammation.
In our study, the increase in IDO activity induced by Ab 1-42 was followed by increased levels of TRP in the prefrontal cortex and hippocampus. These findings are somewhat counterintuitive, and certainly argue against the hypothesis that IDO activation depletes TRP bioavailability for 5-HT synthesis. In contrast with our results, earlier clinical studies have reported that TRP degradation leads to a serotonergic system deficiency which may exert its impact on cognitive symptoms in AD (Porter et al., 2000 (Porter et al., , 2003 . Thereby, our study suggests that the neurobehavioral complications induced by Ab 1-42 do not involve an acute TRP degradation. The increase in brain TRP caused by an inflammatory stimulus, such as Ab 1-42 peptide infusion, could be explained as a compensatory mechanism of the brain in response to acute inflammation.
Most notably, we demonstrated that Ab 1-42 injection precipitated behavioral disturbances coupled with increased kynurenine (KYN) levels and a KYN:TRP ratio with a compatible time course, supporting the involvement of brain KYN metabolism in driving AD symptoms. Corroborating our result, it has shown that a single peripheral injection of KYN was sufficient to induce a deficit in recognition memory in mice (Heisler and O'Connor, 2015) . The observation that the Ab 1-42 injection induced an increase in KYN levels independently of TRP depletion suggests an alternative hypothesis for the involvement of IDO in Ab 1-42 -induced behavioral disturbances, e.g., the generation of neuroactive TRP metabolites. For instance, Myint and Kim (2003) have previously proposed that the activation of IDO during inflammatory conditions switches the metabolism of KYN toward the production of neurotoxic metabolites by microglia cells and that these metabolites are important in the pathogenesis of AD (Guillemin and Brew, 2002) . Of these metabolites, the N-metil-D-Aspartato (NMDA) receptor agonist quinolinic acid (QUIN) may be one of the critical factors in the pathomechanisms of neuronal damage and death in AD (Guillemin and Brew, 2002) , mainly due its roles in reduction of the neurogenesis and the amplification of the inflammatory response within the brain (Heyes et al., 1993) .
Thus, in the present study, we indicate that the activation of the KYN pathway, revealed by the increase of IDO activity and KYN levels in the brain, independently of TRP depletion, is involved in Ab 1-42 -induced cognitive and emotional alterations in mice. Although the QUIN levels were not measured in the current study, we speculate that a shift towards the neurotoxic arm of KP could be driven by Ab 1-42 injection. Further investigations should be aimed at addressing this possibility. To determine the role of the enzyme IDO in Ab 1-42 -induced behavioral alterations, we administered the IDO inhibitor 1-MT twice daily for 1 week before i.c.v. Ab 1-42 injection (experiment 2). The behavioral and neurochemical measurements were conducted at 7 days post Ab 1-42 administration (i.e., the ''peak effect" detected in the experiment 1). We demonstrated that the pharmacological blockade of IDO activation with 1-MT prevented the recognition memory impairment and depressive and anxiety-like responses induced by Ab 1-42 infusion, similar to other studies (Lawson et al., 2013; O'Connor et al., 2009; Salazar et al., 2012) . Therefore, we suggest that behavioral disturbances elicited by Ab 1-42 are driven by IDO activity in the prefrontal cortex and hippocampus of mice.
In this study, we also demonstrated that 1-MT pretreatment attenuated the neuroinflammatory response and the neurotrophic deficiency in the prefrontal cortex and hippocampus of Ab 1-42 -treated mice. This result is relevant because it shows that most of the neuroinflammation caused by Ab 1-42 is mediated by IDO.
This also suggests that IDO is involved in the neurotrophic deficit found in AD. In the present study, 1-MT pretreatment normalized TRP levels and abrogated the increase in KYN production and the KYN:TRP ratio in the prefrontal cortex and hippocampus of Ab 1-42 -injected mice. Therefore, we suggest that increased KYN levels and possibly the neurotoxic end-products of the KP are the potential pathogenic precipitants of cognitive and neuropsychiatric-like behaviors induced by the Ab 1-42 peptide. Here, we can further speculate that the broad spectrum of action of 1-MT was due to the blockage of QUIN production and thus the amplification of the inflammatory response, although possible off-target actions of 1-MT may be involved. Taken together, our study supports the idea that a single i.c.v. injection of Ab 1-42 peptide induces cognitive impairment and emotional disturbances in mice through IDO activation in the prefrontal cortex and hippocampus and that the neuroinflammatory response is the initial step. A summary of the mechanistic explanations can be seen in Fig. 10 . The data in the present study are the first to suggest a mechanistic role for the KP in Ab 1-42 -induced neuroinflammation and behavioral abnormalities in mice.
Conclusions
Our data strongly suggest a critical role for IDO in mediating the cognitive impairment and emotional perturbations induced by Ab 1-42 -related neuroinflammation. The present study is an important step toward understanding the onset of cognitive and neuropsychiatric alterations associated with AD, specifically the link between early memory loss and depression and anxiety, as well as the role of brain cytokines and IDO activation in this mechanism. Thus, we suggest that the KP and its metabolites are important targets for novel therapeutic interventions in AD, providing an alternative or potential adjunct to anti-inflammatory and antiamyloid therapies in alleviating AD symptoms. (À) decrease; underlined: mechanisms demonstrated in this study. First, the proinflammatory activation, as measured by the increase in the levels of proinflammatory cytokines following Ab 1-42 injection caused IDO activation and subsequent increased levels of KYN, which may mediate the observed behavioral disturbances. Hence, KYN accumulation within the brain may activate neurodegenerative pathways via KYN neurotoxic metabolites that ultimately provoke a decrease in neurotrophic factor levels. This neurotrophic deficit could contribute to the observed neurobehavioral complications. Finally, the neuroinflammatory signature induced directly by Ab 1-42 peptide may be caused neurotoxicity partially through iDO-independent mechanisms, such as the disruption of the neuroprotection via down-regulation of neurotrophic factors and anti-inflammatory cytokine IL-10.
